Home » Stocks » TSHA

Taysha Gene Therapies, Inc. (TSHA)

Stock Price: $30.81 USD -0.06 (-0.19%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $31.75 +0.94 (3.05%) Jan 22, 5:48 PM
Market Cap 1.17B
Revenue (ttm) n/a
Net Income (ttm) -27.77M
Shares Out 34.52M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $30.81
Previous Close $30.87
Change ($) -0.06
Change (%) -0.19%
Day's Open 30.87
Day's Range 30.15 - 32.00
Day's Volume 82,001
52-Week Range 19.14 - 32.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 days ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 1 week ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 2 weeks ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc., (NASDAQ: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatmen...

Business Wire - 2 weeks ago

SAN FRANCISCO--(BUSINESS WIRE)--AllStripes (formerly RDMD), a healthcare technology company dedicated to accelerating research for patients with rare diseases, today announced a multiyear coll...

Business Wire - 3 weeks ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 1 month ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 1 month ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 1 month ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 1 month ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 1 month ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 2 months ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment...

Business Wire - 2 months ago

DALLAS & SOMERSET, N.J.--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing adeno-associated virus (AA...

Business Wire - 2 months ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment ...

Business Wire - 3 months ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment ...

Business Wire - 3 months ago

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment ...

About TSHA

Taysha Gene Therapies, a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medi... [Read more...]

Industry
Biotechnology
IPO Date
Sep 24, 2020
CEO
R. A. Session II
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
TSHA
Full Company Profile

Analyst Forecasts

According to 5 analysts, the average rating for TSHA stock is "Strong Buy." The 12-month stock price forecast is 36.80, which is an increase of 19.44% from the latest price.

Price Target
$36.80
(19.44% upside)
Analyst Consensus: Strong Buy